iBio Inc (IBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31+0.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 24.9% |
| Our one-year growth estimate | diamond | -83.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 108.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IBIO — President transition
Dated 2026-05-08
Director — Evert Schimmelpennink: Evert Schimmelpennink resigned from the Board and his position on the Compensation Committee.
Why it matters: Lawsuits can impact iBio's work and money. Investors need clear updates.
Watch forThere are positive news in the litigation that help iBio.
Also watch forThere are negative news in the litigation that hurt iBio's position.
Why it matters: High operating losses show financial problems. This may affect future funding.
Worry ifOperating losses are more than negative $8.37 million in Q3 2026.
Less concerning ifOperating losses improve. They fall below negative $6 million in Q3 2026.
Why it matters: Managing cash burn is key to keeping operations and funding trials.
Worry ifOperating losses go down or cash burn is managed well.
Less concerning ifOperating losses rise a lot beyond current levels.
Why it matters: Dosing the first participant is a key milestone for iBio's clinical development. It shows progress in bringing their treatment to market.
Supportive ifThe first participant is dosed in the IBIO-600 Phase 1 clinical trial by the end of Q2 2026.
Worry ifThe dosing of the first participant is delayed beyond Q2 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$268 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $810 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,896 loss on $10,000 · 59.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Financial news after the offering will show if the company can pay for its projects.
Watch forThe company reports a big increase in cash after the offering.
Also watch forThe company reports money problems or cash does not grow as expected.
Why it matters: If the healthcare sector's revenue growth picks up, it may benefit iBio's performance.
Supportive ifHealthcare sector revenue growth speeds up to 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: Good data would show IBIO-610 can help with obesity. This would boost investor trust.
Supportive ifNew preclinical data shows at least 6.7% fat loss in obese primates.
Worry ifNew data shows no significant fat loss or negative results from IBIO-610 studies.
Why it matters: Advancing clinical trials is key for iBio's growth. Progress here can boost investor confidence.
Supportive ifAnnouncement of successful dosing in the clinical trial by the end of Q2 2026.
Worry ifNo updates or delays in clinical trial dosing progress by the end of Q2 2026.
Why it matters: New data could show that IBIO-610 is a strong treatment for obesity. This may attract investors.
Supportive ifThe presentation shows good results for fat loss and Activin E inhibition at the EASD Meeting.
Worry ifThe presentation shows bad data or no important findings.
Why it matters: New data on IBIO-610 could validate its potential as a treatment for obesity. This could attract investor interest.
Supportive ifThe full dataset on IBIO-610 will be shown at the EASD Annual Meeting. This meeting is from September 28 to October 2, 2026.
Worry ifThe data shows no clear benefits of IBIO-610 over current treatments.
Why it matters: The earnings date will show how the company is doing. It will also give future guidance.
Watch forAnnouncement of the next earnings date with positive guidance or revenue growth.
Also watch forThe next earnings date may come with bad news or more losses.
Why it matters: Managing cash burn is crucial for iBio's financial health. Updates will show how well they are controlling costs.
Worry ifiBio reports lower losses or better cash management in Q3 2026.
Less concerning ifOperating losses increase beyond current levels in Q3 2026.
Why it matters: Advancing IBIO-800 could grow iBio's pipeline. It would also help its market position.
Supportive ifIBIO-800 is moving into a new stage of development. It has strong preclinical data.
Worry ifNo news or delays in IBIO-800 development have been reported.